Ozempic's prescribing information gives a 5 day window: if a dose is missed it should be administered as soon as possible within 5 days after the missed dose, and if more than 5 days have passed the missed dose is skipped and the next dose is given on the regularly scheduled day. That rule belongs to Ozempic alone. Mounjaro and Zepbound use 4 days, Trulicity counts forwards instead of backwards, and Wegovy injection asks how far away the next dose is rather than how long ago the last one was.
There is no single GLP-1 missed dose rule, and the differences are not rounding. Below is what each United States label actually says, why the windows differ, and where the labels stop and a prescriber has to take over.
- Ozempic: a missed dose can be given within 5 days; after that it is skipped. The injection day can move as long as more than 48 hours separate two doses.
- Mounjaro and Zepbound: 4 days (96 hours), with a minimum of 3 days (72 hours) between any two doses.
- Wegovy injection: the rule is written around the next dose, not the last one. More than 2 days away, the missed dose is given; less than 2 days away, it is not.
- The daily products behave differently again: liraglutide reinitiates at 0.6 mg after a gap of more than 3 days, and the oral tablets simply skip the missed day.
What each label says, side by side
Each row is the manufacturer's own wording condensed, taken from the current FDA prescribing information on DailyMed. The last column is the separate rule about moving the injection day, which people often confuse with the missed dose rule.
| Product | Molecule and schedule | One missed dose | Minimum gap between two doses |
|---|---|---|---|
| Ozempic | Semaglutide, weekly | Allowed within 5 days of the missed dose; after 5 days it is skipped and the next falls on the regular day | More than 48 hours |
| Wegovy injection | Semaglutide, weekly | Allowed if the next dose is more than 2 days away; not given if the next dose is less than 2 days away | 2 or more days |
| Mounjaro | Tirzepatide, weekly | Allowed within 4 days (96 hours); after that it is skipped and the next falls on the regular day | 3 days (72 hours) |
| Zepbound | Tirzepatide, weekly | Allowed within 4 days (96 hours); after that it is skipped and the next falls on the regular day | 3 days (72 hours) |
| Trulicity | Dulaglutide, weekly | Allowed if at least 3 days (72 hours) remain until the next dose; otherwise it is skipped | 3 or more days |
| Saxenda | Liraglutide, daily | The once-daily regimen resumes at the next scheduled dose, with no extra dose to make up for it | Not applicable (daily) |
| Victoza | Liraglutide, daily | The once-daily regimen resumes at the next scheduled dose, with no extra dose to make up for it | Not applicable (daily) |
| Rybelsus and Ozempic tablets | Oral semaglutide, daily | The missed dose is skipped and the next is taken the following day | Not applicable (daily) |
| Wegovy tablets | Oral semaglutide, daily | The missed dose is skipped and the next is taken the following day | Not applicable (daily) |
Why the windows are different lengths
The windows track how long each molecule stays in the circulation. Semaglutide's elimination half-life is approximately 1 week, and the Ozempic label goes further: with that half-life, semaglutide will be present in the circulation for about 5 weeks after the last dose. A weekly drug with a weekly half-life can absorb a few days of slippage without the next dose landing on top of a peak.
Tirzepatide and dulaglutide both have an elimination half-life of approximately 5 days, shorter than semaglutide's, and both labels use a shorter window and an explicit 72 hour floor between doses. Liraglutide sits at the other end entirely, with a plasma half-life of approximately 13 hours, which is why it is a daily injection and why its labels talk about reinitiating rather than catching up.
That ordering, 5 days for semaglutide and 4 days for tirzepatide against half-lives of about a week and about 5 days, is the pharmacology showing through the dosing instructions rather than a difference of opinion between manufacturers.
Ozempic and Wegovy are the same molecule with different sentences
This is the pair that causes the most confusion, because both are semaglutide injections from the same company and the rules look unrelated. Ozempic measures backwards from the dose that was missed and allows 5 days. Wegovy injection measures forwards to the next scheduled dose and uses a 2 day (48 hour) threshold, so the same gap is described from the other end.
On a weekly schedule the two sentences describe almost the same window, because 5 days after a missed dose and 2 days before the next one are the same moment on a 7 day cycle. A dose missed two days ago clears the Ozempic test and leaves the next dose 5 days out, which clears the Wegovy test too. Both windows close around the fifth day.
The labels also differ in scope. Wegovy's is the only one of the two that addresses more than one missed injection: if 2 or more consecutive doses are missed, the label describes reinitiating dose escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions. The Ozempic, Mounjaro and Zepbound labels say nothing about consecutive misses at all, which is one of several places where the document runs out and the prescriber does not. The titration each label builds up to is set out in our Ozempic dosage chart and Wegovy dosage chart.
Trulicity counts in the opposite direction
Trulicity is the one weekly label that is written entirely around the next dose. It says the missed dose can be given if there are at least 3 days (72 hours) until the next scheduled dose, and that if less than 3 days remain the missed dose is skipped and the next is given on the regularly scheduled day. Its patient information puts the same rule as a prohibition: do not take 2 doses within 3 days of each other.
Read quickly, that sounds like Mounjaro's rule. It is not. Mounjaro's 4 days runs from the missed dose; Trulicity's 3 days runs to the next one. On a 7 day cycle the two produce different answers in the middle of the week, which is exactly when people go looking for the rule.
The daily products: skip rather than double
The daily products share one instruction, which is that the missed dose is not made up. Saxenda and Victoza both say to resume the once-daily regimen as prescribed with the next scheduled dose and not to administer an extra dose or increase the dose to make up for the missed one.
Liraglutide then adds a rule the weekly injections do not have. Both labels state that if more than 3 days have elapsed since the last dose, treatment is reinitiated at 0.6 mg daily and the escalation schedule is followed again, specifically to reduce the gastrointestinal adverse reactions associated with reinitiation. Saxenda's patient leaflet turns that into an instruction to call the prescriber after 3 days or more rather than a dose to work out alone.
The oral products are the simplest of the set. Rybelsus, Ozempic tablets and Wegovy tablets all say the missed dose is skipped and the next dose taken the following day, with no catch-up and no window.
Where the labels stop
Three questions people arrive with are not answered anywhere in these documents. What a missed dose does to a weight curve is one: no label and no published trial reports it, so there is no percentage to quote. Whether a long gap needs re-escalation on semaglutide or tirzepatide injections is another, addressed only in Wegovy's label and only for 2 or more consecutive doses. The third is what to do when a missed dose collides with insulin, a sulfonylurea or a planned procedure, which is a prescribing question rather than a dosing-window one.
What the escalation rules do tell you is that tolerability, not efficacy, is what the labels are protecting. In SURMOUNT-1, the gastrointestinal events on tirzepatide were mostly mild to moderate and occurred primarily during dose escalation (PMID 35658024), and in STEP 1 nausea and diarrhoea were the most common adverse events on semaglutide 2.4 mg, typically transient and subsiding with time (PMID 33567185). Restarting lower is about that first phase, not about lost ground.
If a gap has already changed the shape of your own timeline, the GLP-1 weight loss calculator will put your current weight against the trial curves rather than against a label, and our piece on the GLP-1 weight loss plateau covers what a flattening curve does and does not mean. For the practical reason a dose gets missed in the first place, usually a pen left in the wrong place, see storing and travelling with a GLP-1.
FAQ
What does the Ozempic label say about a missed dose?
Section 2.1 of the Ozempic prescribing information states that if a dose is missed, it should be administered as soon as possible within 5 days after the missed dose, and that if more than 5 days have passed the missed dose is skipped and the next dose is given on the regularly scheduled day. The same section says the day of weekly administration can be changed as long as at least 2 days (more than 48 hours) separate two doses.
Is the missed dose window the same for Mounjaro and Zepbound?
Yes. Both tirzepatide labels use 4 days (96 hours) after the missed dose, after which the missed dose is skipped and the next falls on the regularly scheduled day. Both also state that the day of weekly administration can be changed as long as the time between the two doses is at least 3 days (72 hours), and the patient information in both adds that two doses should not be taken within 3 days of each other.
Why does Wegovy use a different rule from Ozempic when both are semaglutide?
The two labels frame the same problem from opposite ends. Ozempic measures backwards from the dose that was missed and allows 5 days. Wegovy injection measures forwards to the next scheduled dose: if that dose is more than 2 days away the missed dose is given as soon as possible, and if it is less than 2 days away it is not given. Wegovy is also the only one of the two whose label addresses two or more consecutive missed doses, which it handles by reinitiating dose escalation at a lower dosage.
What do the daily GLP-1 labels say?
Saxenda and Victoza, both liraglutide, say to resume the once-daily regimen with the next scheduled dose and not to take an extra dose to make up for the missed one. Both add that if more than 3 days have elapsed since the last dose, treatment is reinitiated at 0.6 mg daily and titrated again. The oral products, Rybelsus and Ozempic tablets and Wegovy tablets, all say the missed dose is skipped and the next dose taken the following day.
Does missing one dose undo the weight loss?
No label and no published trial reports what a single missed dose does to a weight curve, so there is no figure to quote. What the labels do address is tolerability: Wegovy reinitiates escalation after two or more consecutive missed injections to reduce the risk of gastrointestinal adverse reactions, and the liraglutide labels do the same after a gap of more than 3 days. Both of those rules exist because gastrointestinal events cluster during dose escalation.
Who decides what to do about a missed dose?
Your prescriber or pharmacist. The windows above are descriptions of what the FDA labels say, which is not the same as advice for one person on one regimen. Insulin, sulfonylureas, kidney function, surgery and pregnancy all change the picture, and none of that is visible in a dosing window.
Sources
- OZEMPIC (semaglutide) injection, prescribing information, sections 2.1 and 12.3. Novo Nordisk. DailyMed, label set id adec4fd2-6858-4c99-91d4-531f5f2a2d79
- WEGOVY (semaglutide) injection and tablets, prescribing information, sections 2.4 and 2.5. Novo Nordisk. DailyMed, label set id ee06186f-2aa3-4990-a760-757579d8f77b
- MOUNJARO (tirzepatide) injection, prescribing information, sections 2.1, 2.2 and 12.3. Eli Lilly. DailyMed, label set id d2d7da5d-ad07-4228-955f-cf7e355c8cc0
- ZEPBOUND (tirzepatide) injection, prescribing information, sections 2.3 and 2.4. Eli Lilly. DailyMed, label set id 487cd7e7-434c-4925-99fa-aa80b1cc776b
- TRULICITY (dulaglutide) injection, prescribing information, sections 2.3 and 12.3. Eli Lilly. DailyMed, label set id 463050bd-2b1c-40f5-b3c3-0a04bb433309
- SAXENDA (liraglutide) injection, prescribing information, section 2.1. Novo Nordisk. DailyMed, label set id 3946d389-0926-4f77-a708-0acb8153b143
- VICTOZA (liraglutide) injection, prescribing information, sections 2.2 and 12.3. Novo Nordisk. DailyMed, label set id 5a9ef4ea-c76a-4d34-a604-27c5b505f5a4
- RYBELSUS and OZEMPIC (oral semaglutide) tablets, prescribing information, section 2.1. Novo Nordisk. DailyMed, label set id 27f15fac-7d98-4114-a2ec-92494a91da98
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID: 35658024
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
This article describes what the prescribing information for each product says. It is not medical advice and it is not an instruction to take, skip, move or change any dose. What to do about a missed dose is a decision for your prescriber or pharmacist, who knows the rest of your regimen.